Ajai Chari, MD, Mt. Sinai, explains Daratumumab’s Main Limitation | Length of Infusion in Infusion-related Reactions at Annual Meeting 2018
Browsing: Multiple Myeloma
Ray Comenzo, MD, Tufts Medical Center, shares Preparation & Administration Processes Are Safe | Response Rate Will Improve at Annual…
Ajai Chari, MD, Mt. Sinai , explains, Unmet Need for LenD Refractory Patients | No One Regimen that is Appropriate…
Ray Comenzo, MD, Tufts Medical Center explains, ANDROMEDA Phase 3 Trial | Randomized Trial for Systemic Light-Chain Amyloid at Annual…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., talks about Many Drugs Being Looked at for Multiple Myeloma…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Trials of BCMA BiTE Platform & CAR-T Cell Early…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Novel Endpoints in MRD in Multiple Myeloma Novel Drugs…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., discusses Data from ARROW Trial for Multiple Myeloma Progression-free survival…
Damian J. Green, MD, from Seattle Cancer Care Alliance discusses a New Trial CAR T-Cells Targeting BCMA For Multiple Myeloma…